New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|November 1, 1997
The American Journal of Managed Care
- November 1997
- Volume 3
- Issue 11
Enhancement of Compliance Among Patients with Hypertension
Advertisement
Articles in this issue
almost 29 years ago
Empiric Examination of Physician Behavior in a Changing Healthcare Marketalmost 29 years ago
Healthcare Utilization Among Women with Eating Disordered Behavioralmost 29 years ago
Postpartum Depressionalmost 29 years ago
Pharmaceutical Considerations of Common Herbal Medicinealmost 29 years ago
When Is a Cost-Effectiveness Claim Valid? How Much Should the FDA Care?almost 29 years ago
Treatment Patterns for Heart Failure in a Primary Care EnvironmentAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5